Novo-Nordisk (NVO)

Add to Watchlists
Create an Alert
43.99 +1.12  +2.61% NYSE Apr 16, 5:00PM BATS Real time Currency in USD
View Full Chart
NVO Price Chart
View All Events

NVO Events

Date Type Description
May 20 Misc Citi Swiss Healthcare Investor Day, Zurich
Mar 21 Dividends Amount: 0.6061, Declared Date: Mar 26 2014, Pay Date: Apr 02 2014
Mar 20 Misc AGM Event for Novo Nordisk
Jan 30 Earnings Financial Statement for the Full Year of 2013.
Jan 30 Misc Q4 2013 Novo Nordisk A/S Earnings Conference Call
Jan 09 Splits Ratio: 5:1
Aug 08 Misc Q2 2013 Novo Nordisk A/S Earnings Conference Call
Aug 08 Earnings Q2 2013 Financial Report Release.
May 01 Earnings Novo-Nordisk A/S 2013 First Quarter Earnings Results.
May 01 Misc Novo-Nordisk A/S 2013 First Quarter Earnings Conference Call
View All Performance Charts

NVO Total Returns Comparison

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Novo-Nordisk is up 33.34% over the last year vs S&P 500 Total Return up 22.52%, Eli Lilly up 10.13%, and Alexion Pharmaceuticals up 54.91%.

Get Quote for

PDF Report for NVO

Download Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.

Download NVO Pro Report PDF

Portfolio Strategies Featuring NVO

Did Novo-Nordisk make it into our Portfolio Strategies?
Start your YCharts membership now to find out.

NVO Profile

  • Sector: Healthcare
  • Industry: Biotechnology
  • Headquarters Country: Denmark
  • Headquarters State/Province: N/A
  • Incorporation Country: Denmark
  • Incorporation State/Province: N/A
  • Est. Current Fiscal Quarter End: June 30, 2014
  • Est. Current Fiscal Year End: December 31, 2014
  • Last Fiscal Quarter End: N/A
  • Last Fiscal Year End: N/A

Novo Nordisk manufactures and markets pharmaceutical products and services. Created in 1989 through a merger of two Danish companies dating back to the 1920s, it has become one of the world's leading companies in diabetes care, where Novo Nordisk pursues research into pulmonary delivery systems; other companies, such as Medtronic, have expanded into insulin pump systems. Novo Nordisk also commands large sectors of the markets in haemostasis management, growth hormone therapy and hormone replacement therapy. They are beginning research in the areas of autoimmune and chronic inflammatory diseases, using novel technologies such as translational immunology and monoclonal antibodies. With headquarters in Denmark, Novo Nordisk has international production facilities in seven countries, with affiliates or offices in 76 countries. Novo Nordisk employs approximately 29,000 people globally (as of Q4 2009), and markets its products in 179 countries. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Novo Nordisk has been ranked 25 among 100 Best companies to work for 2010 by Fortune.

Recent Quotes

Symbol Price Chg Chg % Market Cap
NVO 43.99 +1.12 +2.61% 120.97B
Create Watchlist from Quotes

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

Get Started Now

Upgrade to {{}}. Start Your YCharts Membership. Start your {{}} Membership


{{ ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{}} Member? Sign in here.